Supplement claims
FDA warning letter themes for supplement brands
A recent FDA warning letter to OptiHealth Products shows how public marketing copy can create intended-use problems for supplement sellers.
FDA reviewed OptiHealth's website in December 2025 and also reviewed a Facebook page that sent consumers to the company's site to buy products. FDA said claims for a supplement product established intended use as a drug because the claims discussed cure, mitigation, treatment, or prevention of disease.
Theme 1: blog claims count
The letter quoted blog sections about heart disease, diabetes, inflammation, Alzheimer's, Parkinson's, and macular degeneration. FDA did not limit its review to the product-detail page. It read the surrounding content that promoted or supported the product.
Theme 2: social links matter
FDA noted the company's Facebook page and the path from social content to the purchase site. A supplement brand cannot treat social copy as separate from the sales funnel when the post points readers toward the store.
Theme 3: the issue becomes intended use
FDA framed the disease-related language as evidence that the product was intended for drug uses. The letter then discussed new-drug approval and misbranding issues tied to adequate directions for use.
Source
OptiHealth Products, Inc. - FDA warning letter, April 29, 2026
This article summarizes one public FDA letter. It does not tell supplement brands how to write labels, claims, responses, or corrective actions.